Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun:178:104786.
doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3.

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Ka-Tim Choy  1 , Alvina Yin-Lam Wong  1 , Prathanporn Kaewpreedee  1 , Sin Fun Sia  1 , Dongdong Chen  1 , Kenrie Pui Yan Hui  1 , Daniel Ka Wing Chu  1 , Michael Chi Wai Chan  1 , Peter Pak-Hang Cheung  2 , Xuhui Huang  2 , Malik Peiris  1 , Hui-Ling Yen  3
Affiliations

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Ka-Tim Choy et al. Antiviral Res. 2020 Jun.

Abstract

An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.

Keywords: ABSTRACT; COVID-19; Emetine; Homoharringtonine; Lopinavir; Remdesivir; Ritonavir.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Antiviral activity of remdesivir (A), lopinavir (B), homorringtonine (C) and emetine dihydrochloride (D) against SARS-CoV-2 virus in vitro. Infectious viral loads (log10TCID50/mL left Y axis) and viability (normalized to the ATP level of the Vero E6 cells incubated with infection media) under increasing concentrations of the antiviral compounds are shown.
Fig. 2
Fig. 2
Combinational effect of remdesivir and emetine dihydrochloride against SARS-CoV-2 virus in vitro. (A) Dose response matrix of serially 2-fold diluted remdesivir (0–50 μM) and emetine (0–0.781 μM) in Vero E6 cells. The percentage of viral inhibition was normalized based on viral load in logarithm scale (log10RNA copies/mL), using the maximal viral RNA copies with no drug controls as 0% inhibition and the minimal RNA copies determined at 50 μM remdesivir as references. (B) The three-dimensional interaction landscapes of remdesivir and emetine were generated by SynergyFinder (Ianevski et al., 2017) based on (B) the Loewe additive model and (C) the Bliss independence model. Red colour indicates synergy while the green colour indicates antagonism of the two drugs.
See this image and copyright information in PMC

Comment in

  • Does lopinavir really inhibit SARS-CoV-2?
    Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, Gervasoni C, Clementi E, Clementi E. Cattaneo D, et al. Pharmacol Res. 2020 Aug;158:104898. doi: 10.1016/j.phrs.2020.104898. Epub 2020 May 11. Pharmacol Res. 2020. PMID: 32438034 Free PMC article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2) - PMC - PubMed
    1. Andersen P.I., Krpina K., Ianevski A., Shtaida N., Jo E., Yang J. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses. 2019;11(10) - PMC - PubMed
    1. Brown A.J., Won J.J., Graham R.L., Dinnon K.H., 3rd, Sims A.C., Feng J.Y. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 2019;169:104541. - PMC - PubMed
    1. Cao J., Forrest J.C., Zhang X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antivir. Res. 2015;114:1–10. - PMC - PubMed
    1. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001282. In press. - DOI - PMC - PubMed

Publication types

MeSH terms